Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar

By sjmartinez • July 5, 2022

Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, von Büdingen HC, Kou X, Weber K, Greenberg B. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022 Jul 5;66:104025. doi: 10.1016/j.msard.2022.104025. Epub ahead of print. PMID: 36007339.

All clinical trials, All demyelinating disease (CNS), Autoimmune diseases, Devic's syndrome, Neuromyelitis optica spectrum disorder, Patient safety,

Tags: Digestive Diseases, Publications

Efficacy and Safety of Ustekinumab and Vedolizumab for Crohn’s Disease of the Pouch

Park S, Keyashian K, Ho A, Limsui D, Frost S, Vazquez R, Yang E, Ebriani J, Maas L, Parian A, Lazarev M, Parekh N, Sauk[...]

Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy preservation and incorporation of valuable endoscopic innovations thresholds for transoral outlet reduction

Jirapinyo P, Kumar N, Thompson CC, Law RJ, Muthusamy VR, Schulman AR, Sullivan S. Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American[...]

ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease

Farraye FA, Melmed GY, Lichtenstein GR, Barnes EL, Limketkai BN, Caldera F, Kane S. ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am[...]